Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transarterial chemoperfusion for malignant pleural mesothelioma
ACTRN12620001264976Phase 2Recruiting
- Sponsor
- I-MED Radiology Network
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, methotrexate and gemcitabine in pleural mesothelioma, sponsored by I-MED Radiology Network. Primary endpoints: Safety of intra-arterial chemoperfusion for malignant pleural mesothelioma and Efficacy by disease response. Started Jul 2022; status: recruiting.
02
Drugs
cisplatinmethotrexategemcitabine
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on ACTRN12620001264976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620001264976.